siofor 500mg potahovaná tableta
berlin-chemie ag, berlín array - 2418 metformin-hydrochlorid - potahovaná tableta - 500mg - metformin
vimetso 50mg/1000mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 17128 vildagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/1000mg - metformin a vildagliptin
vimetso 50mg/850mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 17128 vildagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/850mg - metformin a vildagliptin
metformin medreg 500mg potahovaná tableta
medreg s.r.o., praha array - 2418 metformin-hydrochlorid - potahovaná tableta - 500mg - metformin
anvildis duo 50mg/1000mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 17128 vildagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/1000mg - metformin a vildagliptin
anvildis duo 50mg/850mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 17128 vildagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/850mg - metformin a vildagliptin
siofor prolong 1000mg tableta s prodlouženým uvolňováním
berlin-chemie ag, berlín array - 2418 metformin-hydrochlorid - tableta s prodlouženým uvolňováním - 1000mg - metformin
siofor prolong 500mg tableta s prodlouženým uvolňováním
berlin-chemie ag, berlín array - 2418 metformin-hydrochlorid - tableta s prodlouženým uvolňováním - 500mg - metformin
siofor prolong 750mg tableta s prodlouženým uvolňováním
berlin-chemie ag, berlín array - 2418 metformin-hydrochlorid - tableta s prodlouženým uvolňováním - 750mg - metformin
sitagliptin accord
accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.